SEARCH

SEARCH BY CITATION

References

  • 1
    Levy M, Backman L, De Husberg B et al.. De novo malignancy following liver transplantation: a single-center study. Transplant Proc 1993; 25: 13971399.
  • 2
    Jonas S, Rayes N, Neumann U et al.. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997; 80: 11411150.
  • 3
    Sheiner PA, Magliocca JF, Bodian CA et al.. Long-term medical complications in patients surviving ≥ 5 years after liver transplant. Transplantation 2000; 69: 781789.
  • 4
    Penn I. Postransplantation de novo tumors in liver allograft recipients. Liver Transplant Surg 1996; 2: 5259.
  • 5
    Jain AB, Yee LD, Nalesnik MA et al.. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998; 15: 1193200.
  • 6
    Frezza EE, Fung JJ, Van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997; 44: 11721181.
  • 7
    Haagsma EB, Hagens VE, Schaapveld M et al.. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001; 34: 8491.
  • 8
    Galve ML, Cuervas-Mons V, Figueras J et al.. Incidence and outcome of de novo malignancies after liver transplantation. Transplant Proc 1999; 31: 12751277.
  • 9
    Pruthi J, Medkiff KA, Esrason KT et al. . Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transplant 2001; 7: 811815.
  • 10
    Instituto Nacional de Estadística. Encuesta de morbilidad hospitalaria 1999. URL http://www.ine.es.
  • 11
    Catalina MV, De Diego A, García-Sánchez A et al.. Caracterización de los tumores malignos de novo en el trasplante hepático. Gastroenterol Hepatol 2003; 26: 5763.
  • 12
    Sánchez EQ, Marubashi S, Jung G et al.. De novo tumors after liver transplantation: a single-institution experience. Liver Transplant 2002; 8: 285291.
  • 13
    Jimenez C, Rodriguez D, Marques E et al.. De novo tumors after orthotopic liver transplantation. Transplant Proc 2002; 34: 297298.
  • 14
    Bellamy CO, DiMartini AM, Ruppert K et al.. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation 2001; 72: 619626.
  • 15
    Xiol X, Guardiola J, Menendez S et al.. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transplant 2001; 7: 971975.
  • 16
    Catena F, Nardo B, Liviano d'Arcangelo G et al.. De novo malignancies after organ transplantation. Transplant Proc 2001; 33: 18581859.
  • 17
    Jain A, DiMartini A, Kashyap R, Youk A, Rohal S, Fung J. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. Transplantation 2000; 70: 13351342.
  • 18
    Jaurrieta E, Casais L, Figueras J et al.. Análisis de 500 trasplantes hepáticos en el Hospital de Bellvitge. Med Clin (Barc) 2000; 115: 521529.
  • 19
    Peyregne V, Ducerf C, Adham M et al.. De novo cancer after orthotopic liver transplantation. Transplant Proc 1998; 30: 14841485.
  • 20
    Berenguer M, Prieto M, Bustamante M et al.. Incidencia de neoplasias internas después del trasplante hepático. Med Clin (Barc) 1998; 111: 481484.
  • 21
    Bessa X, Andreu H, Cirera I et al.. Tumores de novo en pacientes adultos con trasplante hepático. Gastroenterol Hepatol 1997; 20: 442445.
  • 22
    Sheil AGR. Malignancy following liver transplantation: a report from the Australian Combined Liver Transplant Registry. Transplant Proc 1995; 27: 1247.
  • 23
    Su CG, Stein RB, Lewis JD, Lichtenstein GR. Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits Dig Liver Dis 2000; 32: 518531.
  • 24
    Kelly DM, Emre S, Guy SR, Miller CM, Schwartz ME, Sheiner PA. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer 1998; 83: 12371243.
  • 25
    Saigal S, Norris S, Muiesan P, Rela M, Heaton N, O' Grady J. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transplant 2002; 8: 488490.
  • 26
    Vanlemmens C, Bresson-Hadni S, De Monnet E et al.. De novo malignancy following orthotopic liver transplantation for alcoholic cirrhosis [Abstract]. Hepatology 1995; 22 (4 Part 2): 200.
  • 27
    Duvoux C, Delacroix I, Richardet JP et al.. Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis. Transplantation 1999; 67: 418421.
  • 28
    Kauffman HM, Cherikh WS, Cheng Y. Posttransplantation malignancies: a problem, a challenge, and an opportunity. Liver Transplant 2002; 8: 488490.
  • 29
    Duvoux C, Pageaux GP, Vanlemmens C et al.. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 2002; 74: 11031109.
  • 30
    Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death. Liver Transplant 2001; 7 (Suppl. 1): S109S118.
  • 31
    McLaughlin K, Wajstaub S, Marotta P et al.. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transplant 2000; 6: 570574.